Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04873141
Status:
COMPLETED
Last Update Posted:
2021-05-05
First Post:
2021-04-28
Brief Title:
Tocilizumab and Cytokine Release Syndrome CRS In Covid-19 Pneumonia
Sponsor:
Shaheed Zulfiqar Ali Bhutto Medical University
Organization:
Shaheed Zulfiqar Ali Bhutto Medical University
Study Overview
Official Title:
Tocilizumab and Cytokine Release Syndrome CRS In Covid-19 Pneumonia Experience From Single Center of Pakistan
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tocilizumab TCZ interleukin-6 IL-6 newly appeared as treatment of cytokine release syndrome CRS in patients with severe covid-19 associated pneumonia In the present study we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients
Detailed Description:
This observational study was designed just to visualize the efficacy and safety of Tocilizumab an antibody anti-IL-6 receptor in patients with moderate to severe COVID-19 with increased inflammatory markersPatients will be followed until Day 29 after randomization
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None